After Imbruvica Passes Chemo-Free Tests, Shorter Duration Regimens Could Be Next Value-Adds

 
• By Mandy Jackson

AbbVie/Pharmacyclics executives Danelle James and Mohamed Zaki, in an interview at ASH, discussed Imbruvica's worth in chemo-free settings and noted additional value that could be created with shorter durations of treatment in combination regimens.

Ladder made of coins with colorful pills on top suggesting the growing prices of medicine or drugs

More from Anticancer

More from Therapy Areas